Abstract
Outcomes following 50 mg <i>versus</i> 100 mg alemtuzumab in reduced‐intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have